COVID-19

      RT @RichardPAConway: @alhkim presenting COVaRiPAD data on SARS-CoV-2 vaccination. Most mount immune response. Risk of po

      Richard Conway RichardPAConway

      4 years 1 month ago
      @alhkim presenting COVaRiPAD data on SARS-CoV-2 vaccination. Most mount immune response. Risk of poor response BCDT >> MMF >> GCC > MTX/AZA/JAKi/TNFi > immunocompetent. Abstr#0457 #ACR21 @RheumNow https://t.co/lf8cAEWGXf
      RT @DrPetryna: Abst0437 #ACR21 @RheumNow factors assoctd w/poor response to mRNA Covid-19 vaccine in rheum pts Rx w/Ritu

      Olga Petryna DrPetryna

      4 years 1 month ago
      Abst0437 #ACR21 @RheumNow factors assoctd w/poor response to mRNA Covid-19 vaccine in rheum pts Rx w/Rituxan: ⬆️ exposure to RTX over time, ⬇️ IgG levels prior to RTX, short interval btw RTX course & BNT162b2 vacc. RA highest&ANCA-vasculitis lowest probability for a + response. https://t.co/DsrJBlNvr7
      RT @ericdeinmd: #ACR21 Abst#0457: #COVID19 Vaccine Responses In Patients w Autoimmune Diseas
      ⭐️Prosp observ: pre-vax

      Eric Dein ericdeinmd

      4 years 1 month ago
      #ACR21 Abst#0457: #COVID19 Vaccine Responses In Patients w Autoimmune Diseas ⭐️Prosp observ: pre-vax▶️5 mo. ⭐️ 90% +Ab responses, but ⬇️ titer ⭐️MMF 21x⬇️ titer, MTX 4.4x⬇️, AZA 3.5⬇️ ⭐️BCDT: 58, JAK: 2.6, TNF 2.3 ⭐️GC ⬇️ even on <5mg! https://t.co/BGU4CP9M0s @Rheumnow #ACRbest https://t.co/7QhsTGTwnZ
      RT @DrMiniDey: #ACR21 Plenary Abs#0457 @alhkim #COVaRiPAD study:
      👉Patients with inflammatory diseases on #immunosuppr

      Mrinalini Dey DrMiniDey

      4 years 1 month ago
      #ACR21 Plenary Abs#0457 @alhkim #COVaRiPAD study: 👉Patients with inflammatory diseases on #immunosuppression have impaired #SARSCoV2 immunity post-vaccine 👉#Steroids, MMF & B cell depletion therapy more severely affect responses 👉https://t.co/7qTABcpm0h @RheumNow #ACRBest https://t.co/EfuHjh3vw5
      RT @drdavidliew: COVID-19 mRNA vaccination immunogenicity
      (vs immunocompetent):

      TNFi: 2.3x reduction
      JAKi: 2.6x
      AZA: 3.

      David Liew drdavidliew

      4 years 1 month ago
      COVID-19 mRNA vaccination immunogenicity (vs immunocompetent): TNFi: 2.3x reduction JAKi: 2.6x AZA: 3.5x MTX: 4.4x steroids: 9x (but confounded by other meds) MMF/MPA: 21x B cell depleting: 57.7x (but 6m gap probably helps) amazing work led by @alhkim #ACR21 ABST0457 @RheumNow https://t.co/cl5vBpNzvQ
      RT @KDAO2011: Dr. @AlHKim on COVaRiPAD data:
      274 pts chronic inflam dz (RA/SLE/IBD/SpA/MS/SS,/Vasculitis) vs 53 control

      TheDaoIndex KDAO2011

      4 years 1 month ago
      Dr. @AlHKim on COVaRiPAD data: 274 pts chronic inflam dz (RA/SLE/IBD/SpA/MS/SS,/Vasculitis) vs 53 control 👉90% Ab+ response (⬇️3.4X titer) 👉MMF⬇️21X 👉MTX⬇️4.4X 👉AZA ⬇️3.5X 👉BCDT⬇️ 57.7X 👉JAKi ⬇️2.6 X 👉GCs⬇️9X 👉TNFi impaired neutralization delta #ACR21 #plenary @rheumnow https://t.co/b0DgLjDi6E
      COVaRiPad study - Immunosuppression affects COVID-19 vax Ab levels. 247 pts, 90% seroconverted but @ reduced (3.4 fold)

      Dr. John Cush RheumNow

      4 years 1 month ago
      COVaRiPad study - Immunosuppression affects COVID-19 vax Ab levels. 247 pts, 90% seroconverted but @ reduced (3.4 fold) titers. Lowest w/ MMF (21x) and B cell Rx vs MTX/AZA (3-4x). Pts on B cell therapy should wait 6 mos to recv vax #ACR21 Abstr# 0457 https://t.co/1gkCsJSDBk
      RT @RichardPAConway: Our latest article on outcomes of patients with vasculitis and PMR and COVID-19 published in @TheLa

      Richard Conway RichardPAConway

      4 years 1 month ago
      Our latest article on outcomes of patients with vasculitis and PMR and COVID-19 published in @TheLancetRheum . @rheum_covid project with co-leads @SattuiSEMD and @EBRheum . https://t.co/8NTAafdYRA
      RT @_Castillo_Pedro: #ACR2021
      Remember, one reason belimumab is so safe is that it does not completely deplete B cells.

      Pedro Castillo _Castillo_Pedro

      4 years 1 month ago
      #ACR2021 Remember, one reason belimumab is so safe is that it does not completely deplete B cells. Particularly important in times of COVID19. Dr. Petri #GreatDebate @RheumNow
      RT @RichardPAConway: Dr Patel @jeffsparks @zach_wallace_md comparative cohort study on CD-20 inhibitors and COVID. ⬆ï¸

      Richard Conway RichardPAConway

      4 years 1 month ago
      Dr Patel @jeffsparks @zach_wallace_md comparative cohort study on CD-20 inhibitors and COVID. ⬆️ mortality, aHR 2.16 . Abstr#0085 #ACR21 @RheumNow https://t.co/wyfEBWurRi
      RT @drdavidliew: How can we tell whether a patient already on rituximab will have an immunogenic response to Pfizer COVI

      David Liew drdavidliew

      4 years 1 month ago
      How can we tell whether a patient already on rituximab will have an immunogenic response to Pfizer COVID-19 vaccination? Better chance of response if: - RA or SLE, not AAV or IIM - high serum IgG pre-last RTX - longer time since last RTX Israeli data #ACR21 ABST0437 @RheumNow https://t.co/yyuFd0eDH6
      RT @DrMiniDey: Excited for the first full day of #ACR21, reporting for @RheumNow!
      Esp looking forward to:
      ⭐Posters: #E

      Mrinalini Dey DrMiniDey

      4 years 1 month ago
      Excited for the first full day of #ACR21, reporting for @RheumNow! Esp looking forward to: ⭐Posters: #Epidemiology, #PublicHealth, #COVID19, #SpA, #RheumatoidArthritis, #PatientOutcomes ⭐Plenary session ⭐Scientific sessions covering #axSpA, #PsA and more
      RT @RichardPAConway: Meta-analysis from @rheum_covid with @HsiehEvelyn shows that people with rheumatic disease are atâ¬

      Richard Conway RichardPAConway

      4 years 1 month ago
      Meta-analysis from @rheum_covid with @HsiehEvelyn shows that people with rheumatic disease are at⬆️risk of SARS-CoV-2 infection and⬆️mortality from COVID-19. Abstr#0086 #ACR21 @RheumNow #ACRBest https://t.co/B7tWs02gfc
      RT @drdavidliew: COVID-19 has been tough on everyone, but especially tough on our patients in rheumatology.

      We need to

      David Liew drdavidliew

      4 years 1 month ago
      COVID-19 has been tough on everyone, but especially tough on our patients in rheumatology. We need to think about the long-term impacts, but also about how we can do it better next time. @HSpecialSurgery #ACR21 ABST0266 @RheumNow https://t.co/JdOqZ8Svin https://t.co/c0rlY9PfDv
      covid coronavirus virus
      Outcomes of COVID-19 in Patients with Rheumatoid Arthritis
      4 years 1 month ago
      Patients with rheumatic diseases – requiring lifelong immunosuppressants— are at high risk for respiratory and viral infections. Over the past decade, an armamentarium of biologic and targeted therapies has led to better control of disease activity in patients with rheumatoid arthritis. Whether these patients, especially those receiving newer biological and targeted therapies such as JAK inhibitors, are at an increased risk of severe COVID-19

      Catch up on Conference Podcasts

      ×